DDInter406 DDInter1376
Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin and bodily fluids. Although it carries _in vitro_ activity against other mycobacterium, such as _Mycobacterium tuberculosis_, it is generally considered an ineffective treatment in comparison to classic tuberculosis treatments such as [rifampicin] and [isoniazid].
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Clofazimine {u} (Compound) binds {v} (Gene) ABCB1
Clofazimine {u} (Compound) upregulates {v} (Gene) HERPUD1
Clofazimine {u} (Compound) downregulates {v} (Gene) TUBB6
Clofazimine {u} (Compound) causes {v} (Side Effect) Dermatitis
Clofazimine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Clofazimine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Clofazimine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Clofazimine {u} may lead to a major life threatening interaction when taken with {v} Toremifene
Clofazimine {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Clofazimine (Compound) binds ABCB1 (Gene)
Clofazimine (Compound) upregulates HERPUD1 (Gene)
Clofazimine (Compound) downregulates TUBB6 (Gene)
Clofazimine (Compound) causes Dermatitis (Side Effect)
Clofazimine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Clofazimine may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin
Clofazimine may lead to a major life threatening interaction when taken with Toremifene
Clofazimine may lead to a major life threatening interaction when taken with Crizotinib